JAKi are NOT associated w worse safety vs bDMARDs when adjusting for confounding. Did regulators get it wrong? #EULAR2023 @RheumNow #OP0116 https://t.co/ZNk0NI7Ky5

Abatacept use in individuals at risk of RA reduced the rate of progression to RA during the treatment phase and împrovement in clinical symptoms over 2 years in the APIPPRA trial by Cope A, Abstr#OP0130 https://t.co/k0SFDHBRE9

Get Un ‘DRESSED’? Use of #etanercept or #adalimumab for #rheumatoidarthritis. #RCT of dose optimization-observational f/u over 10 yrs with attempts to lower and even d/c Rx in #RA You CAN lower dose in many Pts & even d/c Rx and recapture. X-rays OK @RheumNow #EULAR2023 #OP0131 https://t.co/PGK5SQJ1WU

@RheumNow Safety is pretty good too - this is abatacept we are talking about here. Cost is a different question, as is the pharmacoeconomics, but at least it’s safe. One other thing about the study ⬇️ #EULAR2023 @RheumNow https://t.co/H3AdBsK8t9

Well certainly, despite the absence of synovitis, these pre-RA patients felt better on their 12m of abatacept. They could do more and hurt less. That does count for something for many patients. But wait, there’s more ⬇️ #EULAR2023 @RheumNow https://t.co/3naNdWGMuX

Abatacept for 12m in ACPA pos arthralgias probably doesn’t impact RA progression that much once the abatacept stops… but are there other reasons you might want to give it? Read on in the next tweet⬇️ APIPPRA study #EULAR2023 OP0130 @RheumNow https://t.co/68CViUeWHy

Interesting newer potential theraputics in #handOA discussed at #EULAR2023 - denosumab had clear structure modifying effects in erosive habd OA compared to placebo. Monocentric, placebo controlled, doubke blind phase 2 study of 100 pts. @rheumnow abst#OP0071